Loading…
Reported covered position: Deputy Chief of Staff and Legislative Director, Sen. Kit Bond
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Issues related to Tricare pharmacy issues.
Issues related to competition in the health care marketplace.
Source: Senate LDA
H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act
Patients Deserve Price Tags Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
Rx ACCESS Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act
Consolidated Appropriations Act, 2026
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
National Defense Authorization Act for Fiscal Year 2026
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act
Patients Deserve Price Tags Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
Rx ACCESS Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act
Pharmacy Benefit Manager Transparency Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
Lower Costs, More Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
Pharmacy Benefit Manager Reform Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation, inclusion of PBM reform and other health policies; Issues relating to implementation of the No Surprises Act.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
Hidden Fee Disclosure Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
Hidden Fee Disclosure Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Health Care Affordability Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
Health Care Affordability Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation, inclusion of PBM reform and other health policies; Issues relating to implementation of the No Surprises Act.
Health Care Affordability Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.
Health Care Affordability Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
Health Care Affordability Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
Drug Competition Enhancement Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
Drug Competition Enhancement Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Drug Competition Enhancement Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Affordable Prescriptions for Patients Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Affordable Prescriptions for Patients Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
Affordable Prescriptions for Patients Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
National Defense Authorization Act for Fiscal Year 2026
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
National Defense Authorization Act for Fiscal Year 2026
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
Pharmacy Benefit Manager Transparency Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Pharmacy Benefit Manager Transparency Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
Pharmacy Benefit Manager Transparency Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
Pharmacy Benefit Manager Transparency Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Pharmacy Benefit Manager Transparency Act of 2025
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
HELP Copays Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
HELP Copays Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.
HELP Copays Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation, inclusion of PBM reform and other health policies; Issues relating to implementation of the No Surprises Act.
HELP Copays Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
HELP Copays Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.
CONNECT for Health Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization.
CONNECT for Health Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization.
Lower Costs, More Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Lower Costs, More Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
Lower Costs, More Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Lower Costs, More Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
Lower Costs, More Transparency Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
Pharmacy Benefit Manager Reform Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Pharmacy Benefit Manager Reform Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Pharmacy Benefit Manager Reform Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
Pharmacy Benefit Manager Reform Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
Pharmacy Benefit Manager Reform Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
DRUG Act
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
CONNECT for Health Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization.
CONNECT for Health Act of 2023
Client: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES) · Firm: THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)
P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization.
Issues related to PBM and drug pricing reform, health care transparency and affordability. P.L. 119-75 Consolidated Appropriations Act, 2026. Issues related to the specialty drug market.
Issues related to health plan and PBM transparency, employer sponsored health insurance. Issues related to the No Surprises Act.
Issues related to prior authorization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Issues related to Tricare pharmacy issues.
Issues related to employer sponsored health insurance. Issues related to the No Surprises Act.
Issues related to PBM and drug pricing reform, health care transparency and affordability. P.L. 119-75 Consolidated Appropriations Act, 2026. Issues related to the specialty drug market.
Issues related to competition in the health care marketplace.
Issues related to prior authorization.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Issues related to prior authorization; ACCESS (Advancing Chronic Care with Effective, Scalable Solutions) model
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; P.L. 119-75 Consolidated Appropriations Act, 2026 (H.R.7148) Issues related to the specialty drug market. H.R. 5582/S. 2355, Patients Deserve Price Tags Act
Issues relating to implementation of the No Surprises Act
Issues related to competition in the health care marketplace.
H.R. 3838/S2296 Pharmacy issues related to the National Defense Authorization Act, FY2026 HR. 6400 / S. 4106 - Rx Access, Choice, Cost Equity, and Supply Stability (Rx ACCESS) Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Labor, Dept of (DOL), SENATE
Issues related to prior authorization.
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
Issues related to competition in the health care marketplace.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to prior authorization.
Issues related to competition in the health care marketplace.
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues relating to implementation of the No Surprises Act.
H.R. 3838/S. 2296 Pharmacy issues related to the National Defense Authorization Act, FY2026.
"S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act." Issues related to the specialty drug market. Issues related to transparency.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to competition in the health care marketplace.
P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization.
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
Issues related to prior authorization.
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation, inclusion of PBM reform and other health policies; Issues relating to implementation of the No Surprises Act.
P.L. 117-169, the Inflation Reduction Act of 2022; H.R. 4189/S. 2016, The Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act of 2023; Issues related to transparency and prior authorization.
S. 864/H.R. 247, the Health Care Affordability Act of 2025 and issues relating to extension of Enhanced Advanced Premium Tax Credits (EAPTCs) including in the American Rescue Plan Act (ARPA) and the Inflation Reduction Act (IRA); Issues related to P.L.119-21 (H.R. 1), the One Big Beautiful Bill Act, and budget reconciliation; Issues related to H.R. 2041, the Hidden Fee Disclosure Act of 2025.
Pharmacy issues related to the National Defense Authorization Act, FY2026.
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE
S. 1542/H.R. 2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market; Issues related to transparency.
Filing targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Pharmacy issues related to the National Defense Authorization Act, FY2026.
S. 1542/H.R.2214, the DRUG Act; H.R. 5378 Lower Costs, More Transparency Act; S. 1339, Pharmacy Benefit Manager Reform Act; S.526, Pharmacy Benefit Manager Transparency Act; S. 1040, The Drug Competition and Enhancement Act; S. 1041, The Affordable Prescriptions for Patients Act; Issues related to the specialty drug market.
Issues related to competition in the health care marketplace.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE